aMoon Growth Fund Limited Partnership - 19 Jan 2023 Form 3 Insider Report for Ayala Pharmaceuticals, Inc.

Role
10%+ Owner
Signature
/s/ Yair Schindel on behalf of himself and the sole shareholder of aMoon General Partner Ltd., the sole General Partner of aMoon Growth Fund G.P. Limited Partnership, the sole General Partner of aMoon Growth Fund, Limited Partnership
Issuer symbol
N/A
Transactions as of
19 Jan 2023
Net transactions value
$0
Form type
3
Filing time
30 Jan 2023, 05:37:48 UTC
Previous filing
11 Jun 2021
Next filing
23 Oct 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ADXS Common Stock 560,602 19 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares are held of record by aMoon Growth Fund, Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any.